Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), ...

The deal, first announced last November, would have resulted in the world's biggest pharma company but was ... everyone has been watching Gilead closely to see how it will try to sustain its ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The stock's fall snapped a two-day winning streak.

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

This was the stock's second consecutive day of gains.

Reuters has reported that BMO Capital Markets analyst Evan Seigerman predicted peak sales of $847 million for Gilead's drug. Both the PPAR drugs compete with Intercept Pharma's Ocaliva ...